NASDAQ:MEDP - Medpace Stock Price, News, & Analysis

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) announced its quarterly earnings data on Thursday, November, 1st. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.63 by $0.04. The business earned $179 million during the quarter, compared to the consensus estimate of $175.07 million. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The company's revenue was up 44.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.40 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Medpace.

Medpace updated its FY18 earnings guidance on Monday, October, 29th. The company provided EPS guidance of $2.76-2.82 for the period, compared to the Thomson Reuters consensus estimate of $2.48. Medpace also updated its FY 2018 guidance to $2.76-2.82 EPS.

7 Wall Street analysts have issued 12-month target prices for Medpace's shares. Their predictions range from $35.00 to $63.00. On average, they anticipate Medpace's stock price to reach $42.8333 in the next year. This suggests that the stock has a possible downside of 25.4%. View Analyst Price Targets for Medpace.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Medpace.

Media coverage about MEDP stock has trended somewhat negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medpace earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Medpace saw a drop in short interest in the month of October. As of October 15th, there was short interest totalling 614,007 shares, a drop of 26.7% from the September 28th total of 838,229 shares. Based on an average daily volume of 485,404 shares, the short-interest ratio is presently 1.3 days. Currently, 2.3% of the shares of the company are short sold. View Medpace's Current Options Chain.

Some companies that are related to Medpace include Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI), Dyadic International (DYAI), Vitality Biopharma (VBIO) and BIOQUAL (BIOQ).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.41%), Acadian Asset Management LLC (4.12%), Laurion Capital Management LP (3.11%), Renaissance Technologies LLC (2.20%), Fuller & Thaler Asset Management Inc. (1.75%) and Prudential Financial Inc. (1.07%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., State Board of Administration of Florida Retirement System, Fisher Asset Management LLC, Alambic Investment Management L.P., PNC Financial Services Group Inc., Systematic Financial Management LP, LSV Asset Management and Pendal Group Ltd. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Insider Buying and Selling for Medpace.

MEDP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Laurion Capital Management LP, Penserra Capital Management LLC, Bank of New York Mellon Corp, Acadian Asset Management LLC and Credit Suisse AG. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $57.44.

Medpace has a market capitalization of $2.06 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

The official website for Medpace is http://www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]